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The beginnings and previous breakthroughs
The 2012 Nobel Prize iN ChemisTry cannot be appreciated 
without reference to previous work by Ahlquist and Black. 
In 1948, Raymond Ahlquist (Missoula, Montana, USA, 
1914–1983), Professor of Pharmacology at the Medical 
College of Georgia, USA, published a paper on adrenergic 
nervous transmission, entitled “A study of the adreno­
tropic receptors,” in the American Journal of Physiology 
[1]. But the molecular nature of adrenotropic receptors, 
i.e., receptors for adrenaline (known today as adrenergic 
receptors), would remain unknown until the work of Rob­
ert J. Lefkowitz, one of the 2012 Nobel laureates, in the 
late 1960s. In fact, Ahlquist’s penultimate scientific publi­
Summary. The 2012 Nobel Prize in Chemistry recognized Professors Robert J. Lefkowtiz 
and Brian K. Kobilka for their work on β­adrenergic receptors, which have been the para­
digm for understanding the mechanism of action of receptors coupled to heterotrimeric G 
proteins (GPCRs). In fact, the discovery of hundreds of members of this family of cell­sur­
face receptors has provided a detailed understanding of how cells sense their environment. 
This brief article draws from the summary used by the Royal Swedish Academy of Sciences 
to support its choice of Lefkowitz and Kobilka for the 2012 award. It also considers some of 
the diverse applications of GPCRs. 
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sisted of and how they worked remained obscured for 
most of the 20th Century.”
We live through our senses, whose receptors are located 
on our anatomical surface. Certainly, one of Lefkowitz’s key 
insights was to consider that cells “sense their environment” 
via sensors/receptors and these are, necessarily, located on 
the cell surface. In his approach to unraveling the molecular 
nature of sensors/receptors he selected the adrenaline recep­
tor, which can be easily detected. (Reasons at the origins of 
other scientific discoveries have been similar. Myoglobin and 
hemoglobin structures were first determined because these 
proteins could be easily followed throughout their purifica­
tion due to their color.) Moreover, adrenaline receptors are 
abundantly expressed by cardiac muscle cells and can be 
studied pharmacologically in isolated beating hearts. 
Lefkowitz’s method to detect adrenaline receptors took ad­
vantage of the one used to detect receptors in the thyroid, by 
radiolabeling the ligand, which in the latter case includes the 
hormone thyroxine. Accordingly, soon in his career Lefkow­
itz used radioactivity to trace cardiac receptors for adrena­
line. As noted by the Swedish Academy: “He attached an io­
dine isotope to various hormones, and thanks to the 
radiation, he managed to unveil several receptors, among 
those a receptor for adrenaline: β­adrenergic receptor. His 
team of researchers extracted the receptor from its hiding 
place in the cell wall and gained an initial understanding of 
how it works.” Later on it was demonstrated that adrenaline 
had quite a number of different targets depending on the 
cell; thus far, two alpha and three β subtypes of adrenergic 
receptors have been identified.
While the radioactive detection of β­adrenergic receptors 
was an important contribution to the field of pharmacology, 
the obvious next step was to determine their structure. The 
usual techniques to resolve proteins structure are not readily 
applicable to proteins such as adrenergic receptors that are 
embedded in the plasma membrane, i.e., that are surround­
ed by lipids. Thus, instead, Lefkowitz and his group obtained 
the mRNA sequence encoding the receptor protein, from 
which they could easily decipher the amino acid sequence. It 
was at this moment, as noted by the Academy, that Brian Ko­
bilka entered in scene: “The team achieved its next big step 
during the 1980s. The newly recruited Kobilka accepted the 
challenge to isolate the gene that codes for the β­adrenergic 
receptor from the gigantic human genome. His creative ap­
proach allowed him to attain his goal. When the researchers 
analyzed the gene, they discovered that the receptor was sim­
ilar to one in the eye that captures light. They realized that 
there is a whole family of receptors that look alike and func­
tion in the same manner.”
Interestingly, the β adrenergic receptor was similar to 
rhodopsin, which is the receptor for light. Solid work from 
many laboratories in the field showed that all GPCRs had 
cation [2] was a review on “Adrenergic β­blocking agents,” 
which had been developed before β­adrenergic receptors 
were precisely understood. Indeed, β­blockers can be con­
sidered among the most successful drugs in the history of 
medicine and they remain therapeutically important in a va­
riety of diseases, especially cardiac arrhythmias and hyper­
tension. Due to the reduction in the heart beat rate and 
other calming effects, they may be used off label in stress­
ful situations (for instance before a PhD defense).
In the early 1960s, Sir James W. Black (Uddingston, 
Scotland, UK, 1924–2010) developed the first β­blockers: 
propranolol and pronethalol. Although pronethalol never 
reached the market because of carcinogenicity in mice, pro­
pranolol revolutionized the medical management of cardio­
vascular diseases. According to contrasted information 
available in the Swedish Academy and on Wikipedia, Sir 
James Whyte Black developed his research in both the aca­
demia and the pharmaceutical industry. One of this main 
achievements was the developing of the first marketed be­
ta­blocker, propranolol. He also participated in the devel­
opment of an effective anti­ulcer treatment that consisted of 
another drug (cimetidine) targeting a GPCR (H2 histamine 
receptors). Black’s contribution to developing effective 
therapies for two common diseases was noteworthy, and 
recognized by the 1988 Nobel Prize in Physiology or Medi­
cine. Furthermore, it should be taken into account that the 
development was possible despite little being known about 
their targets: β­adrenergic receptors for propranolol, and 
histamine receptors for cimetidine. Both receptors belong 
to a superfamily known today as “G­protein­coupled recep­
tors” (GPCRs). It was the β­adrenergic receptor that re­
ceived the attention of the Nobel Prize Committee in 2012. 
Molecular nature of β-adrenergic receptors
Robert J. Lefkowitz (New York City, USA, 1943) heads the 
Howard Hughes Medical Institute at Duke University 
Medical Center (Durham, North Carolina, USA) and Brian 
K. Kobilka (Little Falls, Minnesota, USA, 1955) is a pro­
fessor at the Department of Molecular and Cellular Physi­
ology, Stanford University School of Medicine (California, 
USA). The two researchers received the 2012 Nobel Prize 
in Chemistry for: “…groundbreaking discoveries that re­
veal the inner workings of an important family of recep­
tors that enable cells to sense its environment: G­protein–
coupled receptors.” The Swedish Academy also noted 
that: “For a long time, it remained a mystery how cells 
could sense their environment. Scientists knew that hor­
mones such as adrenaline had powerful effects: increasing 
blood pressure and making the heart beat faster. They 
suspected that cell surfaces contained some kind of recipi­
ent for hormones. But what these receptors actually con­
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the same basic structure, i.e. seven transmembrane do­
mains. This observation suggested that these receptors 
originated from an ancestral gene encoding a cell surface 
sensor. GPCRs act as sensors for an enormous number of 
hormones and neurotransmitters active in our cells at every 
instant. Their importance is reflected in the fact that some 
10 % of the genes in the human genome encode GPCRs 
(Fig. 1)—a percentage higher than that of any other protein 
family in the human genome; and there are probably even 
more than the currently estimated 802 GPCR genes in the 
human genome [3b]. As the Academy put it: “Today this 
family is referred to as G­protein–coupled receptors. About 
a thousand genes code for such receptors, for example, for 
light, flavor, odor, adrenaline, histamine, dopamine and se­
rotonin.” 
GPCRs are subdivided into different classes: class A 
(Rhodopsin­like), class B (Secretin­like), class C (Gluta­
mate Receptor­like), and other (Adhesion, Frizzled, Taste 
type­2, etc.) [3b]. Some 70 % of all GPCRs are of the class A 
type. The receptors in this class include those for odorants/
pheromones, underlining the importance of smell in evolu­
tion. There are also “orphan” receptors, whose endogenous 
hormones/neurotransmitters are still unknown. In the last 
10 years, however, some of these orphan receptors, such as 
GPR55, now known to be the lysophosphatidylinositol re­
ceptor [29], have found their origins.
In recognizing the biomedical importance of the role 
played by GPCRs  in a variety of diseases, the Swedish Acad­
emy pointed out that “about half of all medications achieve 
their effect through G­protein–coupled receptors.” Although 
this percentage was overestimated—the real number lies 
around 35–40 %—it is clear that the number of “GPCR 
drugs” far exceeds that targeting any other family of proteins. 
Some of these drugs are life­saving while others improve the 
quality of life, for instance in cases of depression or anxiety.
GPCR-mediated signaling
In the last 30 years of the 20th century, hundreds of scien­
tists participated in deciphering the mechanism by which 
GPCRs communicate the presence of extracellular signals 
to the cell interior. Because of their work, GPCR­mediated 
signaling is better understood than that of any other recep­
tor family. Among the key proteins in this process are the G 
proteins, whose discovery and characterization merited a 
Nobel Prize in Physiology or Medicine in 1994, awarded to 
GPRC SUPERFAMILY
(802 GENES)
Class A
(701 genes)
Class B
(15 genes)
Class C
(24 genes)
Other
62 genes
Olfactory
(359 genes)
Fig. 1. Classification of the human GPCR family. The main subfamilies are: class A (rhodopsin-like), class B (secretin-like), and class C (glutamate-like); other 
includes Frizzled, taste type-2, and unclassified receptors. Modified from Bjarnadóttir et al., 2006 [3b]. The number of GPCR receptors in the human ge-
nome is not yet known; therefore, the numbers in the figure are estimates from data in Pubmed and Wikipedia.
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the puzzle was greatly aided by Kobilka’s contribution, in 
which he helped to solve the structure of G­protein­cou­
pled β2­adrenergic receptors (Fig. 2) [33]. In contrast to 
soluble proteins such as myoglobin or hemoglobin, which 
are easily isolated and crystallized and their 3D structure 
readily resolved using X­ray diffraction, membrane pro­
teins pose a challenge, as their purification and crystalliza­
tion are difficult.
Rhodopsin, which is very abundant in the retina, was 
extracted by Palczewski and collaborators [30,31], facili­
tated by their use of mixed micelles of nonyl β­d­glucoside 
and heptanetriol. Thus, a highly purified protein prepara­
tion could be crystallized from solutions containing vary­
ing amounts of detergent and amphiphile; these crystals 
provided the first structure of a seven transmembrane pro­
tein [31]. The laboratory of Palczewski also carried out 
Alfred G. Gilman and Martin Rodbell for “their discovery of 
G­proteins and the role of these proteins in signal transduc­
tion in cells.” Further information on these G proteins and 
their action as mediators between GPCRs and intracellular 
components can also be found at the Nobel Prize web site. 
The first G proteins to be identified and characterized were 
those that regulate, either positively (Gs) or negatively (Gi), 
the activity of adenylate cyclase, the enzyme that produces 
cAMP, an important intracellular messenger. Indeed, the 
title of Gilman’s Nobel lecture was: “G Proteins and Regula­
tion of Adenylyl Cyclase.” In the meantime, a number of 
other G proteins and cAMP­independent signaling path­
ways have been discovered.
The history of GPCRs took an unusual turn with the dis­
covery that they can bind to a variety of proteins other than 
G proteins. Consequently, GPCRs are now more accurately 
referred to as heptaspanning membrane receptors. It was 
Lefkowitz who, in 1987, reported that adrenergic receptors 
interact with a protein he named β­arrestin, because of its 
apparent involvement in receptor deactivation [3]. Lefkowitz 
and colleagues later observed that β­arrestin also participat­
ed in G­protein­independent signaling. They reported that 
β2­adrenergic receptors signal the relevant mitogen­activated 
protein kinase signal transduction pathway via an arrestin­
dependent pathway that is independent of G protein cou­
pling [41]. Adenosine receptors are likewise able to bind to a 
number of proteins, some of them extracellular, such as ade­
nosine deaminase, and others intracellular, such as caveolin, 
the heat shock cognate protein hsc73, and alpha­actinin 
[4,5,12,15,20,22,35–38]. The full diversity of GPCR­related 
signaling options stems from the ability of these receptors to 
form homodimers and even heteromers. Recognition of these 
features provides many new opportunities to exploit the 
structural and functional diversity of these receptors, e.g., in 
drug discovery (see below).
GPCR structure
The final paragraph of the statement of the Royal Swedish 
Academy of Sciences in support of its choice for the 2012 
Nobel Prize in Chemistry is: “The studies by Lefkowitz and 
Kobilka are crucial for understanding how G­protein–cou­
pled receptors function. Furthermore, in 2011, Kobilka 
achieved another breakthrough; he and his research team 
captured an image of the β­adrenergic receptor at the exact 
moment that it is activated by a hormone and sends a signal 
into the cell. This image is a molecular masterpiece—the 
result of decades of research.”
There has been a general consensus in the GPCR field, 
which year after year seemed ripe for a Nobel prize, that 
the award would have not been possible without the reso­
lution of the 3D structure of these proteins. This piece of 
Transmembrane
domains of β2AR
Fig. 2. Structure of the β2-adrenergic receptor-Gs complex. The overall 
structure shows the β2-adrenergic receptor (β2AR) bound to an agonist 
and engaged in extensive interactions with a heterotrimeric Gs, which is 
composed of Gsa, Gb, and Gg subunits. A specific nanobody (Nb35) binds 
to the Gs protein between the a and b subunits. Crystallization, for purpos-
es of structure resolution, is facilitated by NB35 and by the lysozyme of T4 
bacteriophage (T4L) fused to the N-terminus of the β2-adrenergic recep-
tor. Data taken from the protein data bank cited in the report by Rasmus-
sen (2011) [33]. (Reprinted by permission from Macmillan Publishers Ltd.).
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them. GCPRs are not the only cell­surface receptors, as 
these also include ionotropic and enzyme­linked receptors, 
which are not coupled to G proteins (Fig. 4). However, as 
noted above, GPCRs are the most abundant membrane re­
ceptors in mammals and they have led to the recognition of 
“partial agonists,” “full agonists,” “inverse agonists,” “neu­
tral antagonists,” “biased agonism,” and “selectivity.”
The signal given by a partial agonist is lesser than that 
achieved by the full agonist, which is usually the natural 
hormone/neurotransmitter. Classical antagonists are 
known today as neutral antagonists although many com­
pounds initially considered as neutral are indeed inverse 
agonists, that is, they bind to the receptor but counteract 
the response of agonists and reduce the constitutive activity 
of GPCRs. This definition makes sense only if the GPCR is 
active even in the absence of agonists. Such constitutive ac­
tivity was indeed shown by Lefkowitz and his group, using 
mutant or over­expressed receptors in heterologous cells 
[13,25]. There are also several diseases, such as congenital 
night blindness and male precocious puberty, that are 
caused by mutations in GPCR genes such that the encoded 
receptors have high constitutive activity [40]. Furthermore, 
many (non­mutated) GPCRs display natural constitutive 
activity, which has raised interest in inverse agonist devel­
opment in drug discovery programs. 
 Biased agonism describes the activation of different signal­
ing pathways by different molecules acting on a given receptor 
[39]. It is an important consideration in the design of mole­
pioneering work using infrared­laser atomic­force microsco­
py to reveal the native arrangement of rhodopsin, which 
forms paracrystalline arrays of dimers in mouse retinal disc 
membranes [17] (Fig. 3).
The methodology for other GPCRs that are less abun­
dant in natural sources is far more complex and involves 
the design of fusion proteins containing part of the receptor 
and motifs that facilitate crystallization. For example, a 
common strategy to promote crystallization is to fuse the 
protein with the lysozyme from T4 bacteriophage and to 
delete the carboxy­terminal tail, which has high conforma­
tional flexibility [42] (Fig. 2). These pseudo­receptors are 
over­expressed in heterologous systems and then further 
purified and crystallized using specific approaches. The 
first receptor structures resolved accordingly were those of 
the β2­adrenergic [10,34] and the A2A adenosine [23] re­
ceptors. The contribution of the laboratory of Raymond 
Stevens, at the Scripps Research Institute in California, to 
obtaining these structures was fundamental. 
GPCRs in pharmacology
An appreciation of the terms agonist (a compound that acti­
vates the receptor), antagonist (one that triggers the inac­
tive conformation of the receptor), and allosteric modulator 
(a compound that modulates the effect of the agonist) is es­
sential to understanding receptors for hormones or neu­
rotransmitters and the activities of the drugs that bind to 
Fig. 3. Atomic force microscopy images of dimer arrays of rhodopsin in native retinal disc membranes. (From [17]; reprinted by permission from 
Macmillan Publishers). 
50 nm 15 nm
(5 nm)-1
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may occur, i.e. there are receptors that may be found as 
monomers in the cell surface. Homodimers have led to a di­
mer­based pharmacology that is very robust in defining use­
ful parameters for drug development [9,18,19]. Yet, from a 
functional point of view, the monomeric or dimeric structure 
of a given receptor is largely irrelevant. This is not the case 
for heteromer formation. Indeed, if GPCRs deserve another 
Nobel Prize it will likely be for novel insights into their het­
eromeric forms.
A GPCR heteromer is defined as a macromolecular 
complex composed of at least two different receptor units, 
both functional, with biochemical properties that demon­
strably differ from those of the individual components [16]. 
In fact, heteromer­specific signaling relies on a precise qua­
ternary structure of the whole complex [28]. The first re­
ported heteromer for a given neurotransmitter was that 
formed by the kappa and delta opioid receptors [24]. The 
first identified heteromer formed by two receptors for two 
different neurotransmitters/neuromodulators was that con­
taining the adenosine A1 and dopamine D1 receptors [21]. 
Several other heteromers were subsequently reported, 
proof that the GPCR heteromer receptor field is gaining 
momentum in the 21st century. There are two open ques­
tions concerning the molecular aspects of heteromeriza­
tion: the size(s) of the heteromer(s) and the receptor: G 
protein stoichiometry. Finding answers to them will re­
quire imaginative approaches and powerful techniques, in­
cules with therapeutic potential. Selectivity is another impor­
tant concept in receptor pharmacology and drug discovery. A 
selective compound that binds, e.g., to β2 adrenergic recep­
tors, would have at least 100­fold more potency for this sub­
type than for any other subtype of adrenergic receptor.
The future: structure and function of GPCR 
heteromers
The impressive research leading to the 2012 Nobel Prize in 
Chemistry was centered on “monomeric” receptors, includ­
ing a seminal work co­authored by Leftowitz, in which the 
mechanism of action of a single GPCR molecule coupled to 
one G protein was described [14]. Unlike membrane recep­
tors of other families, e.g., T­cell receptors and insulin recep­
tors, the expression of class A rhodopsin­like GPCRs as 
monomers on the cell surface was a common assumption. 
But this view is progressively changing based on findings, 
such as those from our laboratory, in which we determined 
that A2A receptors are present on the cell surface as homodi­
mers [6]. Atomic force microscopy images of retinal rhodop­
sin also show GPCRs as arrays of homodimers (Fig. 3). Re­
cently, Kobilka’s laboratory reported that the µ­opioid 
receptor crystallizes as a two­fold symmetrical dimer through 
a four­helix bundle motif formed by transmembrane seg­
ments 5 and 6 [26]. It is therefore likely that many cell­sur­
face receptors are in the form of homodimers. Exceptions 
Fig. 4. The three main types of cell-surface receptors. Examples are given in parentheses.
ION CHANNELS
(acetylcholine nicotinic receptor)
GPCRs
(serotonin receptor)
RECEPTOR TYROSINE KINASES
(insulin receptor)
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cluding resolution of the 3D structure of macromolecular 
complexes formed by heteromers and multiple G proteins. 
At present, complexes consisting of three different recep­
tors (heterotrimers) and dimers of heterodimers (heterotet­
ramers) have already been reported [7,27]. 
From an evolutionary point of view, heteromers seem 
to provide diversity in hormone­ or neurotransmitter­me­
diated responses. The dopamine receptors subtypes 1 (D1) 
and 2 (D2) offer an appropriate example of functional di­
versity. Whereas D1 is coupled to a Gs protein and D2 to a 
Gi protein, the D1­D2 receptor heteromer couples to a Gq 
protein. G proteins are the mediators that control the con­
centration of second messengers, with Gs and Gi control­
ling cAMP and Gq controlling Ca2+ levels. Thus, while in­
dividual receptors signal via cAMP, the heteromer signals 
via a totally different cascade, one that is triggered by cal­
cium ions [32]. Another example of the differential role of 
heteromers is provided by the adenosine A1­A2A receptor 
heteromer. Adenosine regulates glutamate release from 
cortical neurons; the regulation of neurotransmitter release 
via A1 receptors is negative but it is positive when A2A re­
ceptors become activated. The mystery of why nerve termi­
nals express both A1 and A2A receptors to regulate gluta­
mate release was solved when heteromers of A1­A2A 
receptors were identified and their functions elucidated 
[8,11]. Specifically, these heteromers constitute a switch 
mechanism by which low and high concentrations of ade­
nosine inhibit and stimulate, respectively, glutamate re­
lease. By intra­heteromer crosstalk, the neuron senses the 
extracellular concentration of adenosine and responds ac­
cordingly [8,11]. In summary, the heteromer may both in­
crease and decrease neurotransmitter release, something 
that would be impossible to achieve with just one adenos­
ine receptor subtype. Promising applications can be ex­
pected as novel heteromers are identified and novel het­
eromer­specific functions are discovered.
Drug development based on GPCR monomers, such as 
screening drugs in heterologous systems expressing a sin­
gle receptor, was successful in the 20th century but, at least 
thus far, progress in the 21st century has been slow. Per­
haps one way to accelerate GPCR drug discovery is to focus 
on GPCRs and heteromers. A two­state dimer receptor 
model is now available to understand the mechanism of ac­
tion of GPCRs and to interpret data obtained from drugs 
interacting with dimers, and even from mixtures of mono­
mers and dimers [9,19]. By contrast, heteromers are dis­
tinct entities such that a given drug will have different af­
finities and different efficacies depending on the heteromer. 
Cell models expressing receptor heteromers would allow 
the identification of novel pharmacological profiles [9] and 
would broaden the therapeutic potential of drugs targeting 
GPCRs while lowering the incidence of side effects.  
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